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Abstract
Reactive oxygen species (ROS) have been associated with a wide variety of 
human diseases and disorders. The ability of these molecules can incapacitate 
antioxidant activity leading to an imbalance between oxidants and anti-oxidants, 
with the latter being more pronounced. ROS are no strangers to immune cell 
relationships and function and consequently the development of autoimmune and 
inflammatory diseases. The collateral damage of excessive ROS (collectively called 
Oxidative stress) to the cells or tissue due to nucleic acid damage and oxidation of 
macromolecules such as proteins and lipids is linked to the manifestation, malfunc-
tion and translation to the disease state of cells. Contrary to this view, recent studies 
have shown that ROS have protective roles in certain autoimmune and inflamma-
tory diseases. Despite significant advances in our understanding of inflammatory 
and autoimmune diseases, therapeutics for these diseases still need further develop-
ment and identification of new targets for improved therapeutic effect. ROS mol-
ecules and inflammation modulators appear before disease development making 
them great therapeutic targets with the potential to inhibit disease manifestation.
Keywords: reactive oxygen species, antioxidants, immune cell, autoimmune, 
inflammatory disease, oxidative stress
1. Introduction
1.1 Reactive oxygen species
Reactive Oxygen Species (ROS) are by-products of chemical reactions that 
involve a one-electron reduction of oxygen, leading to the production of a diatomic 
oxygen radical known as superoxide. Superoxide serves as a precursor for multiple 
ROS generation. The oxygen anion can be produced mainly by enzymatical or 
non-enzymatical means. Enzymes such as Phagocytic Nicotinamide Adenine 
Dinucleotide Phosphate Oxidase (NADPH Oxidase), cytochrome P450–dependent 
oxygenase, and the proteolytic conversion of cytosolic Xanthine dehydrogenase 
can produce singlet-oxygen molecules [1, 2]. The enzymatic generation of super-
oxide is the main generator of superoxide, especially NADPH oxidase. However, 
non-enzymatic generation can also cause a significant increase in reactive species. 
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This occurs mostly in the mitochondria during ATP synthesis. The electron trans-
port chain (ETC) has been reported to consist of centers that can leak electrons 
to oxygen, thereby causing a reduction of the oxygen [1]. Additionally, reduced 
coenzymes and prosthetic groups such as flavins and metal ions can directly trans-
fer an electron to oxygen. The produced singlet-oxygen undergoes dismutation, 
catalyzed by the enzyme superoxide dismutase, to produce hydrogen peroxide, a 
more stable and less reactive molecule. The increased availability of ROS can lead to 
an imbalance between oxidants and antioxidants, resulting in a state that is known 
as oxidative stress [2]. During this state, the various deleterious effects of ROS such 
as disruption of cellular homeostasis, structures and function are manifested in the 
cell. Therefore, ROS overproduction has a pathological role in the development of 
various conditions and diseases, including inflammation and autoimmune disease.
1.2 Inflammation
Inflammation is a none-specific immune response of cells or tissues to a stimulus 
such as a pathogen, cell damage, or toxicity that plays an important role in host 
defense. This response involves the signaling molecules, immune cells and blood 
vessels. The process is marked by the proliferation of inflammatory cells like 
monocytes, neutrophils, and lymphocytes. These cells release various molecules 
such as ROS, pro-inflammatory cytokines and various enzymes that have the ability 
to induce oxidative stress in the target tissues [3]. Therefore, inflammation and 
oxidative stress can co-occur, and one process can induce the other and vice versa.
Inflammatory responses can be complex as they involve multiple interactions of 
many cells and mediators. There are four major patterns of inflammatory response 
that are also common mechanisms of diseases. These patterns depend on the type 
of hypersensitivity. Two or more types of hypersensitivity can occur at once in a 
patient.
1. Type 1: This type of hypersensitivity is mediated by immunoglobulin (Ig) 
E that is found on the surface of mast cells. The interaction between this 
antibody and a respective antigen causes the release of inflammation me-
diators such as serotonin and histamine, among others. The release of these 
molecules causes diminished blood pressure due to vasodilation, increased 
vascular endothelium permeability, and bronchoconstriction [4]. Interesting-
ly, increased activation of mast cells can cause a systemic response that causes 
anaphylactic shock. Mediators that are released by mast cells can also recruit 
inflammatory cells such as eosinophils and increase the production of PAF, 
leukotrienes, prostaglandins and cytokines like TNF-α, IL-1, IL-3 and IL-5 
[5]. This results in a sustained inflammatory response and reduces transient 
respiratory efficiency.
2. Type 2: This type of hypersensitivity is triggered by the binding of antibodies, 
IgG and IgM to the cellular antigens, causing tissue destruction. The binding of 
antibodies results in lysis of the cell via the in-situ fixation complement. Ig M 
is an effective inducer of this process [5]. Fixation of complement is an impor-
tant cause of cell injury, and it can cause opsonization as well as being an active 
recruiter of inflammatory cells.
3. Type 3: This is heavily marked by serum sickness due to increased circulat-
ing immunocomplexes. The deposition of these immunocomplexes can lead 
to injury at the site of deposition (usually vascular beds). This is because the 
complexes are efficient activators of the classical pathway of the complement 
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cascade [6]. The properties of the complexes determine which vascular bed 
they are deposited in. This deposition is precise and distinct in pathophysiol-
ogy of different diseases such chronic autoimmune diseases such as systemic 
lupus erythematosus [5, 6]. Certain inflammatory responses have a confection 
of features of type 2 and type 3 hypersensitivity.
4. Type 4: This type of hypersensitivity usually takes longer to occur after antigen 
exposure and is also referred to as delayed-type hypersensitivity. It is typified 
by antigen-specific T cells activation after 24–48 hours of exposure to antigen. 
The antigens modify cellular proteins and these proteins are targeted by T 
cells. CD8+ T cells interact with the antigen presented by MHC-I and become 
activated [7]. This causes the T cell to kill all the cells that are presenting that 
antigen. Antigen-presenting cells also display antigens via the MHC-II that 
activates CD4+ T cells and causes the release of cytokines [5]. Activation of the 
two T cell activation leads to an increase in antigen-specific response, leading 
to hypersensitivity reaction over time. In some events, an immediate inflam-
matory response is initiated due to a positive response. The positive response 
occurs when the T cells are pre-primed as a result of prior ongoing exposure to 
the pathogenic antigen [6]. During this event, the interaction between the T 
cells and macrophages causes the release of TNF- and IFN, which are respon-
sible for the inflammatory response. Other types of hypersensitivity responses 
that are triggered by cellular components of the immune system can also be 
referred to as type 4 even without being antigen specific (Table 1).
Inflammation is triggered to eliminate harmful agents so as to minimize the 
effects of the injuries. However, minimal inflammation (acute inflammation) 
usually does not inhibit these effects and prolonged inflammation (chronic inflam-
mation) is associated with multiple diseases and conditions [3]. Acute inflamma-
tion is known to be part of the innate immune response as it is the initial response 
to a stimulus. In this phase of inflammation, platelets and granulocytic cells like 
basophils, eosinophils and mast cells are activated. These cells migrate from the 
blood vessels to the site of injury and release molecules that initiate, stimulate and 
attenuate inflammation for a short period [8]. For this to occur, the blood vessel 
becomes more permeable, consequently leading to the escape of proteins, outflow 
of fluids known as exudate and migration of other blood cells from the vessels to the 
site of inflammation, causing a swelling known as edema on the site. Neutrophils 
are the primary cells during this phase and they tend to engulf the foreign materials 
and organisms together with other debris. As neutrophils are short-lived cells, they 
are replaced by monocytes that differentiate into macrophages [8]. The acute phase 
usually resolves after hours or days, or even within a week. The persistent presence 
of monocytic cells due to ongoing and long-term response to stimuli leads to the 
development of chronic inflammation.
During chronic inflammation, there is a continuous accumulation of macro-
phages and lymphocytes at the site of inflammation due a persistent stimulus from 
the immune system [9]. The prolonged inflammatory response that might last for 
a week, months and in some cases a lifetime, will eventually lead to tissue injury. 
This can be induced by viral or certain bacterial infection and in some individu-
als, genetic polymorphism of inflammation mediators and cell receptors can also 
induce and favor extensive chronic inflammation [10]. In addition to the accumula-
tion of macrophages, chronic inflammation is also marked by the proliferation of 
fibroblasts and small blood vessels. In rare cases when the inflammatory response 










Type Mediator Components Antigen & Antibody Principle Phenotype Time/Period Example




Antibody: fixed on mast 
and basophil cells
Destruction of cells 






Early ≤3 hours Asthma, Bee sting, Rhinitis




or exogenous, fixed on 
cells
Antibody: Free in 
circulation
Annihilation of normal 







Rhesus hemolytic disease, 
autoantigen-induced cell damage, 
Drug-induced anemia
3 IgG/IgM Compliment system 
components, 
Phagocytes, Killer cells




Antibody: free in 
circulation
Antigen–antibody 










SLE, Lung arthritis, 
glomerulonephritis, vasculitis











soluble or fixed on cell.
Antibody: none





≥ 24 hrs from 
stimulation
Granuloma formation, Diabetes 
Mellitus,
Table 1. 
Summary of types of hypersensitivity.
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Granulomatous inflammation is a specific type of chronic inflammation that 
is marked by the presence of crystalline materials embedded into the tissues. 
Macrophages are the predominant effectors and they are recruited by T cells. Th1 
cells have been reported to be the major mediators of granulomatous inflammation 
reactions [11]. Following the activation of Th1 cells by the antigens presented on 
MHC-II on the macrophages, Th1 secretes IFN-γ and other cytokines. These mol-
ecules then transform macrophages into activated tissue macrophages. Although 
the activated macrophages have increased capacity to eliminate foreign pathogens, 
they have a tendency to fuse and form multinucleated giant cells which forms con-
centric nodules that are known as granulomas [12]. Central necrosis can develop in 
these granulomas. This phenomenon has have been observed in infections caused 
by M. tuberculosis and other pathogens [13]. Such a phenomenon has also been 
reported in some autoimmune diseases.
Although inflammation is an essential process to the host defense, it can easily 
induce excessive tissue damage, resulting in acute or chronic tissue damage, organ 
or system dysfunction with fatal outcomes. Studies have shown increasing evidence 
of the involvement of chronic inflammation in autoimmune diseases, including 
but not limited to rheumatoid arthritis (RA), inflammatory bowel disease (IBD) 
systemic lupus erythematosus (SLE), gout, and diabetes [14]. This happens when 
inflammatory activity causes the production of autoimmune molecules and reac-
tive species that sensitizes the immune system to a non-pathogenic component of 
the body.
1.3 Autoimmune diseases
Autoimmune diseases are chronic conditions that result from the loss of immune 
tolerance to self-antigens, causing the immune system to attack the organisms’ 
healthy cells, tissues, and/or organs. Autoreactive T cells and autoantibodies are 
identified as the major attackers of self-antigen [15]. The differentiation and 
activation of these key attackers are still not fully elaborated. These disorders can be 
classified into two major groups, organ-specific autoimmune diseases and multiple 
organs or systemic autoimmune diseases. Different types of autoimmune diseases 
have been found to share common phenotypic features, from clinical signs and 
symptoms to genetic factors and pathophysiology mechanisms [16–18]. However, 
it is likely that some inducing factors may differ as different autoimmune diseases 
target different cells, organs and systems. Additionally, environmental factors also 
play a role in the onset of these diseases.
Factors that are common in different autoimmune diseases include but is not 
limited to the following features.
1. Pathology: The phenotypic manifestation of autoimmune varies, depending on 
the affected or target cell or system. However, the major pathogenic role is con-
tributed by the phagocytic T cells and B cells. Other predominant cells include 
macrophages, neutrophils, and CD8+ T cells. Other cells that also contribute to 
the pathogenesis of autoimmune diseases are T helper cells, especially Th1, Th9 
and Th17 [19]. The array of complex biological functions displayed by these 
cells such as cytokine production, antigen presentation, exosome release, the 
release of neutrophil extracellular traps (NETs), ROS, Arginase 1 and pro-
grammed death-ligand 1 have been implicated in the induction of autoreactive 
T cells and B cells as well as tissue damage and inflammation [20]. Abnormali-
ties in the function of cells that participate in the classic immune response 
such as higher expression of IL-6, interferon-α, APRIL and BAFF can cause 
the dysregulation of adaptive immune cells [21]. These cells then go on to cause 
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cell death either directly or indirectly by releasing cytokines, ROS, RNS and 
prostaglandins. Interestingly, specialized pro-inflammatory neutrophils with 
enhanced NETs and inflammatory cytokine production capacity have been 
found in the peripheral blood of patients suffering from different autoimmune 
diseases [15]. These cells have a low density due to altered buoyancy properties.
Peripheral tissues contain activated regulatory T cells that control inflamma-
tion and autoimmunity responses by eliminating malfunctioning neutrophils, 
lymphocytes and macrophages. Cells such as CD25+ and CD4+ T cells can 
secrete anti-inflammatory cytokines that can reduce Th1, Th9 and Th17 activ-
ity, thereby preventing autoimmune disease development [22]. However, their 
function can be inhibited by environmental agents such as pathogenic toxins 
or smoking.
2. Risk factors
a. Gender: Statistically women are more susceptible to autoimmune diseases 
than men. With nearly 5% of the total global population suffering from 
these diseases, 80% of the reported cases are women [23]. Pathophysiology 
in the progression of autoimmune diseases in women tends to be different 
from men and can cause polyautoimmunity. Factors that contribute to this 
are differences in hormonal orientation and genetic factors [24]. High levels 
of estrogen, progesterone and prolactin have been implicated in the develop-
ment of autoimmune diseases.
b. Age: Diseases like systemic lupus erythematosus (SLE) and type1 diabetes 
mellitus tend to have a high severity when the onset is early [25]. However, 
other autoimmune diseases are not influenced by the time of onset, e.g. 
rheumatoid arthritis and Sjogren’s syndrome.
c. Environmental agents: One of the most crucial environmental autoimmunity 
triggers is infectious agents. Viruses like the Epstein–Barr virus and cyto-
megalovirus have been implicated in multiple autoimmune inductions [26]. 
However certain viruses like the hepatitis B virus have the putative ability to 
protect against autoimmune disease development.
d. Genetics: The genetic risk factors of autoimmune diseases can be divided 
into two groups, the common factors and the specific factors. Autoimmune 
phenotype is determined by a combination of common and disease-
specific alleles interacting with environmental and epigenetic factors [27]. 
Autoimmune phenotypes have also been confirmed to be the outcomes 
of nonspecific diseases genes [28]. Additionally, genetic ancestry can also 
influence the heterogeneity and variation of the clinical manifestation 
disease [29]. Certain population subgroups and races have been associated 
with having a relatively high frequency of autoimmune diseases risk alleles. 
However, genetic risk factors only confer a small risk and can only explain a 
limited proportion of heritability in relation to autoimmune diseases [30]. 
Investigated population and additive and non-additive factors should be 
considered when assessing heritability in autoimmunity.
e. Other autoimmune conditions: People with a history of autoimmunity or 
who have an existing autoimmune infection are at higher risks of develop-
ing another autoimmune disease [31]. Diverse manifestation of disease 
7
Reactive Oxygen Species in the Development and Resolution of Autoimmune and Inflammatory…
DOI: http://dx.doi.org/10.5772/intechopen.99988
phenotype originating from the same gene causes a condition known as 
polyautoimmunity [17]. The coexistence of more than two autoimmune 
diseases in a patient leads to a syndrome known as multiple autoimmune 
syndromes (MAS). MAS is known to favor the pathogenesis of other autoim-
mune diseases. Dermatological autoimmune disease is present in most MAS. 
Aside the existence of other autoimmune conditions, the development of 
MAS is associated with genetic, immunologic, infectious, and psychological 
factors.
3. Subphenotype: Signs and symptoms of autoimmunity are shared across a wide 
range of autoimmune diseases. Symptoms such as fatigue, dizziness, arthritis, 
alopecia, and Raynaud’s phenomenon and high levels of cytokines are common 
in most autoimmune diseases [32]. However, these diseases can have a hetero-
geneous spectrum if the disease course is dependent on the patient. Addition-
ally, the disease phases differ from one patient to another and even within the 
same patient [33]. This can increase the challenge in acquiring a better under-
standing of autoimmune diseases because although subphenotypes are similar, 
they can change depending on the diseases activity and duration [34].
4. Recurrence risk: Complex diseases such as autoimmune diseases tend to cause 
phenotype clusters in the family of the infected individual. This aggregation 
usually occurs in a higher frequency than what is observed in the general popu-
lation [29]. The presence of different autoimmune diseases in the members of 
the nuclear family is known as familial autoimmunity. When a specific autoim-
mune disease occurs in the family, it is known as familial autoimmune diseases 
[18]. Familial autoimmunity is common than a familial autoimmune disease 
(Figure 1).
Figure 1. 
Development of autoimmune disease. Following the generation and maturation of immune cells in the bone 
marrow and thymus, the cells undergo a series of processes to produce immuno tolerant cells. A small number 
of T and B cells evade this process and form autoreactive T and B cells. However these cells are harmless until 
acted upon by genetic or environmental factors autoantibody can trigger autoimmunity for long term.
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2. Pathogenic foreign bodies, ROS, inflammation and autoimmunity
Production of ROS in phagocytic cells during the oxidative burst is essential 
to the elimination of pathogens during an immune response. However, it is also 
connected with the promotion of inflammation and tissue damage. Interestingly, 
recent studies have demonstrated that phagocyte derived ROS plays a role in the 
regulation of inflammation as well as providing protection against autoimmunity. 
This is mainly because chronic inflammation in multiple pathologic conditions has 
been associated with ROS deficiency.
The activation of the oxidative burst is highly marked by increased uptake of 
oxygen in the neutrophils. The consumed oxygen is primarily converted to singlet-
oxygen molecules. This leads to an increase of the membrane-permeable hydrogen 
peroxide due to elevated dismutation activity within the phagocytes. This initiates 
the generation of various radical and non-radical ROS molecules via the activity of 
myeloperoxidase. In the events of oxidative burst, the NADPH oxidase complexes 
serve as one of the major generators of ROS but the localization and timing of 
the products depend on the stimulus [35]. Despite the localization and efficiency 
of ROS production, a high concentration of the molecules has been reported to 
cause the inactivation of proteins and enzymes via the adduct formation due to 
lipid peroxidation products [36]. Among the enzymes that are inactivated by this 
mechanism is NOX2, a potent producer of superoxide molecules. To counter this 
inhibition, phagocytic cells recruit cytochrome-b558 from the lysosomal pool via 
the soluble NSF attachment receptor 23 (SNARE) [37]. This enables the continuous 
production of ROS even after the inactivation of NOX2. This mechanism ensures 
the efficient eradication of pathogens and has been reported to potentially play a 
vital role in the regulation of autoimmunity [38]. The failure to move the NOX2 
to the endosomes due to decreased Ncf4 expression in phagocytic cells can cause 
autoimmune responses but without the elimination of pathogenic molecules. 
Notably, increased activity of NOX2 is known to cause the destruction of mem-
branes because of lipid peroxidation and this results in the leakage of the endosome 
contents such as antigens [39]. This process allows the presentation as well as 
cross-presentation of antigens to MHC-I. ROS production is therefore essential for 
the eradication of intracellular pathogens [39, 40].
Some evidence of the role of ROS in the maturation of dendritic cells and the 
increased expression of MHC-II molecules has been proposed, however, this is met 
with conflicting research results that NOX2-ROS production does not play a role 
in the maturation, differentiation and production of cytokines. This is despite its 
important role in the elimination of intracellular foreign stimuli. Nevertheless, ROS 
enables regulated presentation of antigen by MHC-II via the oxidation of cathepsin 
cysteinyl thiols which prevents excessive protein degradation in early phagosomes. 
Intracellular foreign pathogen infections such as bacterial and fungal infections 
have been reported to be persistent in conditions where NOX2 activity is lacking 
[41]. NOX2 is also involved in backup mechanisms of pathogen capturing such 
as the formation of neutrophil extracellular traps (NETs) [42]. NETs are mainly 
composed of chromatin coated in antimicrobial peptides and proteases. During 
NETs formation, ROS are required for the release of elastase while myeloperoxidase 
participates in the formation of azurophilic neutrophils granules that facilitate 
histone degradation in the nucleus [42].
2.1 ROS in inflammatory and autoimmune development
Oxidative damage caused by ROS can generate deleterious byproducts consist-
ing mainly of proteins and lipids that are modified into peroxides. These molecules 
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play important roles in the pathogenesis of several diseases. These molecules have 
also been implicated in the pathophysiology of cell death and tissue damage. Some 
of these have the ability to cause immunogenic reactions by inducing pathogenic 
antibody release in diseases such as systemic lupus erythematous, alcoholic liver 
disease, diabetes mellitus, inflammation, degenerative diseases, and rheumatoid 
arthritis. Aldehydic by-products that form adducts with proteins make up two-
thirds of molecules that have been implicated in these conditions.
Stress-induced by ROS or any other factor compromises the antioxidant activ-
ity within a cell can lead leading to an imbalance in the pro-oxidant/antioxidant 
balance. The prevalence of this phenomenon has been shown to increase lipid 
peroxidation. Lipid peroxidation is the degeneration of polyunsaturated fatty acids 
by free radical activity. The process involves three steps: initiation, propagation and 
termination. In the first step, a reactive radical extracts a hydrogen molecule from 
the methylene group. This leaves an unpaired electron on the carbon that combines 
with molecular oxygen in the propagation phase which then forms reactive peroxyl 
radicals that react with other lipids thereby forming hydroperoxides. Notably, 
peroxyl can produce fatty acid radicals and this can cause a chain reaction that 
causes lipid peroxide toxicity. Lipid peroxidation can also be induced by incidences 
of exacerbated conjugated dienes, 4-hydroxyl-2-nonenal modified proteins, 
malondialdehyde modified proteins and 4-hydroxynonenal among other molecules. 
Products of lipid peroxidation such as 4-hydroxy-2-alkenals can form the an adduct 
with the amino groups of proteins, leading to ROS induced protein modification. 
Modified proteins that gain the function of an aldehyde are highly immunogenic. 
ROS-induced lipid peroxidation and protein modification are likely to co-occur, and 
the two processes can mutually induce each other. Some products of these processes 
can avidly react with antioxidants including glutathione and cofactors of ketogluta-
rate dehydrogenase causing further damage to the antioxidant response.
Lipid peroxides are not bystanders when it comes to the destruction of cellular 
membranes, cell-matrix and the accelerators in the development of conditions 
such as atherosclerosis in arthritis especially rheumatoid arthritis. The destruction 
of the cell membrane can cause the leakage of cellular content, thereby induc-
ing an inflammatory response as the phagocytic cells attempt to clean the debris. 
The process of debris clearance can percussively cause tissue damage. During this 
process two sets of macrophages are activated, the first set is M1 which is classically 
activated, and the second set is M2, which is alternatively activated. M1 is known 
for excessive production of toxic production which M2 tries to resolve by produc-
ing molecules like EVG and VEGF. The difference in function is made vivid by the 
distinction in the cytokine profile of the two sets. M1 releases excessive proinflam-
matory cytokines IL1, IL6 and ROS which ultimately causes cell death by activating 
death receptors and/or caspases. M2 on the other hand releases anti-inflammatory 
cytokines like IL-4 and IL-10. In situations that lead to excessive tissue injury, 
there is little to no anti-inflammatory response as compared to proinflammatory. 
Aside from this, oxidation of low-density lipoproteins can cause the upregulation 
of chemokines, adhesion molecules and glycan end-products, thereby inducing an 
increased inflammatory response. Inflammation in the presence of oxidative stress 
is known to result in the nonenzymatic degradation of proteins through glycoxida-
tion. Glycoxidation of immunoglobins produces modified immunoglobins which 
can induce a systemic inflammatory response. Neo-epitopes created by protein 
modifications can be recognized by toll-like receptor-4, advanced glycan end-
product receptors, and scavenger receptors as invasive and can induce pathogen-
associated molecular patterns in the immune system that will ultimately lead to 
autoimmunity. Additionally, there is a correlation between ROS-altered biomol-
ecules and the severity score of autoimmune and inflammatory diseases.
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2.2 Examples of inflammatory and autoimmune diseases and the ROS
2.2.1 Systemic lupus erythematosus
SLE is a complex autoimmune disease that affects at least 0.04% - 0.2% of every 
100,000 people. The disease has a high prevalence in childbearing age women. 
This disease is marked by the increased presence of autoantibodies that target 
nuclear components and inflammation. This usually occurs in organs like the lungs, 
kidney, and joints. Although the exact cause of SLE remains not fully understood, 
a genetic predisposition that promotes the formation of lupus has been purported. 
Additionally, single nucleotide polymorphism in the Ncf2 gene that causes reduced 
ROS production is known to increase the likelihood of SLE occurrence. The promot-
ing role of ROS deficiency in lupus-like phenotype has been demonstrated in mice 
where mutation of the Ncf1 shows high levels of anti-DNA, anti-histone, and anti-
RNA antibodies with elevated deposits of Ig G and complement C3 in the glomeruli 
[43]. This contributes to the development of clinical signs of Arthritis, lung hemor-
rhage and enhanced glomerulonephritis. Increased risk of atherosclerosis is another 
feature of SLE. Atherosclerosis is developed due to endothelial dysfunction which is 
linked to a diminished bioavailability of nitric oxide and an increased generation of 
ROS. Studies in lupus-prone mice have shown increased activity of NADPH oxidase 
coupled with elevated systolic blood pressure and renal disease, a typical symptom 
of lupus [44]. ROS in SLE can play a double role depending on the stage of the 
disease. On one hand, it can be essential in the prevention of autoimmune diseases 
during the early stage, but it may exacerbate damage during the late stage of the 
disease.
2.2.2 Type 1 diabetes (diabetes mellitus)
Type 1 diabetes is a metabolic disease that results from the dysregulation of 
insulin due to the autoimmune destruction of β-cells in the pancreas. The dis-
ease emerges at an early age and is manifested as high levels of blood sugar. The 
hyperglycemia-induced onset of diabetes has been linked to excessive oxidative 
stress damage. Mouse model-based experiments have demonstrated that ROS 
plays a key role in disease development of the disease [45]. For example, non-obese 
diabetic mice that produce is prone to type1 diabetes, contrary to their ROS defi-
cient counterparts [46]. Reducing the ROS levels is known to help in transforming 
macrophages to M2 phenotype. Unlike M1, M2 is not a proinflammatory phenotype 
and does not cause diabetes mellitus. Cells taken from diabetic patients have been 
found to exhibit increased production of singlet oxygen molecules and a depletion 
of antioxidants or loss of antioxidant enzymes activity. Hyperglycemia coupled 
with oxidative stress can lead to macromolecule damage such as protein damage, 
DNA, and lipids. Islet β-cells are highly susceptible to this damage, which displaces 
the activation of signaling pathways [47].
2.2.3 Rheumatoid arthritis
Rheumatoid arthritis is an autoimmune and inflammatory disorder charac-
terized by persistent joint inflammation, which can result in the production of 
autoantibodies, destruction of the bone and cartilage at the site of inflammation. 
Mutations in the genes that encode components involved in oxidative stress have 
been found to play a role in the progression of rheumatoid arthritis. By using 
murine-induced arthritis, pristine-induced arthritis (PIA), gene regions that 
are involved in the regulation of different phases of the disease and its severity 
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have been identified using mouse models [48]. The loss of NOX2 function due to 
polymorphism of the Ncf1 gene is associated with the manifestation of the arthritis 
phenotype. Recovery of NOX2 function shows protection against the development 
of the disease. Sever collagen-induced arthritis with excessive cartilage destruc-
tion has also been found in mice with a mutated Ncf1 gene [43]. Additionally, 
female mice with a mutated Ncf1 gene develop spontaneous arthritis postpartum. 
Autoimmune responses that target cartilage-derived molecules play a vital role in 
the development of arthritis. The recognition of type II collagen bound to MHC-II 
by T cells is important for disease initiation. However, this alone is not enough to 
break the immune tolerance. When the recognition of type II collagen by T cells is 
coupled with the dysregulation of NOX2, chronic collagen-induced arthritis is initi-
ated [49]. Notably, tolerance break can still occur by modulation of T cell activation. 
Single nucleotide polymorphism in genes that encode for components of NADPH 
oxidase complex such as Ncf4, Ncf2, and Rac2 and genes of antioxidants enzymes 
have been linked to arthritis incidence. Low copy numbers of the Ncf1 gene are a 
common occurrence in patients with rheumatoid arthritis. Therefore, an increased 
copy number of the gene can lead to protection against the development of rheuma-
toid arthritis.
The protective role of ROS in rheumatoid arthritis seems to oppose its destruc-
tive role in joint inflammation. During arthritic inflammation, reactive species 
can exacerbate inflammation while contributing to tissue damage via collagen 
degradation. Overproduction of ROS is also known to cause cartilage degradation in 
osteoarthritis. This is achieved by inducing apoptosis in the chondrocytes, cells that 
are essential for the formation and function of the cartilage [50]. The prevalence 
of ROS coupled with inflammation causes the disruption of tissue homeostasis 
and depletion of antioxidants. Hydrogen peroxide and hydroxyl species react with 
membrane lipids, causing lipid peroxidation and promoting cartilage degeneration 
while inhibiting self-repair [51]. Cartilage degeneration is achieved by affecting 
the structures of the structural proteins found on the joint, such as collagen and 
proteoglycan, causing the chondrocytes to enter the stage of senescence or cell 
death, which can eventually lead to subchondral sclerosis and meniscal and liga-
ment damage. ROS and inflammatory cells are contained in the synovial fluid in the 
joint. Their intense activity not only causes the thinning of the proteoglycan layer 
and collagen fiber but can also cause functional impotence to the DNA mismatch 
repair system. This activates the NF-kB and the overproduction of metalloprotein-
ase and DNA adducts such as 8-oxo-hydroxy-7,8-dihydro-2′-deoxyguanosine there 
by contributing to DNA damage and cell arrest. With reduced antioxidant activity, 
arthritis progression is favored.
2.2.4 Chronic granulomatous disease
Chronic granulomatous disease (CGD) also known as Bridges-Good or Quie syn-
drome is a rare inheritable immunodeficiency disorder that affects phagocytes such 
as neutrophils, monocytes and macrophages. These phagocytes lose their capability 
to form reactive oxygen compounds such as superoxides, and their capability to 
eliminate invasive pathogens will therefore, become greatly reduced. CGD is char-
acterized by recurrent bacterial or fungal infection and other dysregulated inflam-
matory responses, leading to the formation of granulomatous and development of 
other inflammatory disorders such as colitis. Clinical manifestation of CGD includes 
pneumonia, adenitis, subcutaneous and hepatic cellulitis, lymphadenitis, osteomyeli-
tis, and sepsis. Clinical studies have also shown the involvement of the genitourinary 
system and gastrointestinal tract in granulomas [52]. CGD is caused by a reduction in 
ROS production due to defective activity of the NADPH complex’s NOX2. The defect 
Reactive Oxygen Species
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is a result of mutations in the NOX2 catalytic subunit gene gp91phox. About 70% of all 
reported CGD cases are found in males and they are X-linked. Mutations in the Ncf1 
and Ncf2 which are recessive autosomal inherited account for a large number of cases 
[53]. These mutations can cause reduced ROS production and disable the ability to 
form NETs, leading to reduced efficiency in pathogen elimination. Interestingly, CGD 
patients have reduced long term memory immunity. A reduced long term memory 
in CGD patients and mice may can be due to the relation between the number of 
neutrophils, NOX2 normal activity and percentage of memory B cells. ROS is known 
to directly influence the process of memory B cells, and hence a loss of function of 
NOX2 will reduce this process. Contrary to a reduced number of memory B cells, 
Cd19+ B cells and immature Ig, the D + CD27- B cells availability increases in patients 
[54]. ROS also plays a role in the activation and proliferation of B cells. According to in 
vitro studies, the neutralization of ROS in B cells is associated with the attenuation of 
B cell receptor signaling. CGD patients with Ncf1 mutation have increased expression 
of type 1 IFNs, which is comparable to 1 IFNs in SLE patients. Type 1 IFNs are known 
to cause autoimmune disease by inducing the differentiation of dendritic cells capable 
of presenting organisms own materials to the phagocytic immune cells [55]. This puts 
CGD patients at a high risk of developing SLE and other autoimmune diseases, includ-
ing juvenile idiopathic arthritis, antiphospholipid syndrome, and IgG nephropathy.
2.2.5 Sepsis
In septic patients, the loss of redox balance is usually the common cause of 
severe inflammatory response syndrome. The inflammation is caused by the 
reactive species from neutrophils and macrophages. The inflammation phase of the 
disease is marked by reduced mitochondrial ATP synthesis and continuous uptake 
of antioxidants by affected cells. The antioxidants aim to fight the deleterious activ-
ity of ROS and RNS such as reversible and irreversible oxidative modifications of 
nucleic acids, lipids, and proteins. The oxidative modification of complex lipids of 
the mitochondrial inner membrane such as cardiolipin worsens the mitochondrial 
dysfunction by causing the release of cytochrome c [56, 57]. This causes further 
reduction of ATP synthesis while elevating the production of reactive species. 
Excessive and persistent ROS in turn inhibits the translocation of Nrf2, which 
jeopardizes the antioxidant response mechanism.
2.2.6 Psoriasis
Psoriasis is an immune-mediated chronic inflammatory skin disease that speeds 
up the growth cycle of skin cells. The disease comprises numerous comorbidities 
and the multifactorial etiology of cardiovascular diseases, metabolic syndrome, 
and type 2 diabetes [58]. The pathogenesis of psoriasis is heavily marked by oxida-
tive stress. However, ROS is reported to have protective effects in psoriasis. In mice 
models with induced psoriasis, elevated levels of ROS will increase the functional-
ity of T regulator cells as well as the expression of indoleamine 2,3-dioxygenase. 
Increased functionality of T regulator cells results in the reduction of circulating 
Th17 cells [20]. The protective effects of ROS are further supported by evidence 
showing the exacerbation of Psoriasis in Ncf1 mutated mice [59]. This suggests that 
the normal functionality of NOX2 plays a role in the attenuation of psoriasis.
2.2.7 Gout
Gout is one of the most understood and manageable systemic rheumatoid 
diseases. It is a disorder of purine metabolism that results in the formation of 
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monosodium urate crystals that are deposited in and around the joints. This is 
mostly due to longstanding hyperuricemia. The urate crystals can induce the release 
of inflammatory cytokines from monocytes and neutrophils, which cause immense 
inflammation [60]. The onset of gout attack can last for at most 10 days and then 
disappear, but the crystals remain present in the joint area. These crystals can 
induce the formation of large NETs aggregates that end up trapping and degrading 
the pro-inflammatory mediators. This in turn will limit and resolve the inflamma-
tion [61]. The formation of NETs in gout is dependent on the availability of ROS, 
and a deficiency in ROS can result in a chronic state for the disease. Therefore, a 
functional oxidative burst is critical for the maintenance of immune tolerance and 
the resolution of inflammation in gout.
3. ROS in inflammation resolution and autoimmune regulation
The effects of ROSs autoimmunity appears to be more complicated than previ-
ously anticipated. ROS is thought to be solely a by-product of the process involved 
in the cellular response to inflammation or infectious stimuli. However, recent 
findings have attributed ROS to have vital roles in cellular regulatory and inflam-
mation restraining processes. As their role in numerous cell functions is elaborated, 
it is now understood that these functions cannot occur without the presence of 
ROSs. Despite this, the tissue, cell type and time point on which ROS act as anti-
inflammatory and immunoregulators are not yet elucidated.
The deficiency of NOX2 has been found to play a key role in the induction 
of multiple autoimmunity conditions. This is true even in severe bacterial and 
fungal infections. Inflammatory and autoimmune diseases such as Corhn-like 
inflammatory disease, idiopathic arthritis and CGD can co-occur. Animal model 
experiments as well as genome-wide studies have shown a relationship between the 
polymorphism of Ncf1 and the occurrence of many arthritic diseases [62]. Ncf1 is 
a cytosolic subunit of NOX2 whose polymorphism signifies diminished production 
of superoxide. Mutation in the Ncf1 gene which results in loss of NOX2 function has 
been reported to increase susceptibility to T cell autoreactive activation, cartilage 
oligomeric matric protein-induced arthritis, and collagen-induced arthritis among 
others [28]. Additionally, NOX2 derived ROS have been found to have regulatory 
roles in T-cell dependent nervous system diseases such as multiple sclerosis and 
Guillan-barre syndrome. Interestingly, NOX2 is also a regulator of autoantibody 
production and autoimmune inflammation. Therefore, NOX2 activity, especially 
ROS generation has a crucial preventative effect on the development of autoim-
munity and can regulate chronic inflammation [63]. However, it is important that 
NOX2 is viewed not as a regulator of disease susceptibility but as a regulator of 
disease severity.
The protective role of ROS in inflammatory and autoimmunity is not universal. 
In type 1 diabetes, ROS deficiency is associated with safeguarding from diseases, 
especially in non-obese diabetic animal model. Thayer et al. reported the essential 
role of macrophage ROS in mediating effector function for CD4+ T cells autore-
activity and autoimmune diabetes pathogenesis [64]. NOX2 generated ROS is also 
vital in the execution of islet reactivity. However, mutations in the Ncf1 gene which 
eventually leads to NOX2 malfunction and reduced ROS availability has been found 
to significantly alter the effector function of macrophages and T-cell subsets [43]. 
Additionally, collagen antibody transfer which develops independently of phago-
cytic immune cells can induce arthritis. This phenomenon can be exacerbated by an 
increase of Ncf1 gene expression. Furthermore, non-classical autoimmune diseases 
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of increased inflammation even in the absence of NOX2 and ROS [41, 63]. This 
shows that certain cases ROS deficiency can be linked to the protection against 
disease.
4. Conclusion
The development of autoimmunity is defied by a wide range of mechanisms, 
regulatory cells and tolerance mechanism, which when not properly functioning 
or are inefficient, fail to decelerate the effects of the interplay of environmental, 
genetic, and immunological factors. Faults in the immune tolerance mechanism 
consequentially leads to inappropriate cell death or survival or failure to clear debris 
which are involved in the pathogenesis of autoimmune diseases. The failure of these 
systems and the eventual development of autoimmune diseases is aided by inflam-
matory modulators. Interestingly, this process occurs before the full development 
of diseases, making the modulators a potential therapeutic target. As such, they 
can also be used as control points to prevent the exacerbation of the autoimmune 
diseases. Targeting inflammatory modulators can, therefore, offer opportunities for 
the development of novel diagnostic methods and effective therapy in the future.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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